Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

Urology
Hendrik Van Poppel, Sten Nilsson

Abstract

Gonadotropin-releasing hormone (GnRH) agonists currently form the mainstay of management of advanced prostate cancer. They effectively suppress serum testosterone levels, which in turn inhibits tumor growth. However, the initial response to GnRH agonists is a transient increase in the serum testosterone levels. Known as a testosterone surge, this can lead to a worsening of symptoms and can adversely affect survival. Therefore, much interest exists in the development of a new class of drugs-GnRH antagonists-which produce immediate suppression of luteinizing hormone and testosterone without a testosterone surge. The most promising GnRH antagonist to date is degarelix.

References

Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Oct 8, 1998·The New England Journal of Medicine·M A EisenbergerB A Lowe
Aug 15, 2001·Urology·G J Bubley
Dec 6, 2001·Lancet·J A Huirne, C B Lambalk
Jun 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Andrew LoblawUNKNOWN American Society of Clinical Oncology
Aug 13, 2004·European Urology·Dorothea Weckermann, Rolf Harzmann
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Miljenko V PilepichDavid Grignon
Jun 21, 2005·BJU International·Ramesh ThurairajaAmit Bahl
Apr 21, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H Van PoppelL Collette
Sep 18, 2007·Human Reproduction·J A HuirneC B Lambalk
Oct 9, 2007·European Urology·Axel HeidenreichUNKNOWN European Association of Urology

❮ Previous
Next ❯

Citations

May 21, 2014·Nature Reviews. Clinical Oncology·Yien Ning Sophia WongJohann de Bono
Apr 24, 2014·European Journal of Clinical Pharmacology·Niels Eckstein, Bodo Haas
Jan 16, 2014·Cancer Metastasis Reviews·Michael A AugelloKaren E Knudsen
Oct 22, 2014·The Journal of Experimental Medicine·Enrico VelardiMarcel R M van den Brink
Jul 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen E Knudsen, Howard I Scher
Sep 10, 2011·Therapeutic Advances in Urology·Laurent Boccon-GibodBo-Eric Persson
Feb 2, 2013·Therapeutic Advances in Urology·Neal D Shore
Sep 15, 2009·Drugs·James E Frampton, Katherine A Lyseng-Williamson
Mar 25, 2010·Drugs·Emma D Deeks
Nov 27, 2009·Expert Opinion on Therapeutic Patents·Gábor Mezo, Marilena Manea
Dec 4, 2009·Expert Review of Anticancer Therapy·Laurent Boccon-GibodBo-Eric Persson
Aug 30, 2013·Expert Opinion on Pharmacotherapy·Ferenc G RickAndrew V Schally
Nov 16, 2011·The Journal of Sexual Medicine·Renee Sorrentino
Feb 9, 2010·Trends in Endocrinology and Metabolism : TEM·Karen E Knudsen, Trevor M Penning
Nov 15, 2008·Trends in Endocrinology and Metabolism : TEM·Ilpo HuhtaniemiBo-Eric Persson
Jun 15, 2012·BJU International·F SchröderT E Keane
Mar 16, 2012·International Journal of Urology : Official Journal of the Japanese Urological Association·Hein Van Poppel, Laurence Klotz
Nov 14, 2015·Nature Reviews. Cancer·Philip A WatsonCharles L Sawyers
Jun 14, 2015·Urologic Oncology·Takahiro KimuraShin Egawa
Jun 4, 2015·Bone Marrow Transplantation·E VelardiM R M van den Brink
Sep 3, 2016·World Neurosurgery·Andrew J Fabiano, Saby George
May 10, 2017·Expert Opinion on Pharmacotherapy·Timothy N ClintonGanesh V Raj
Sep 14, 2012·The Journal of International Medical Research·Y XuB Wu
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dong-Yi ChenWen-Kuan Huang
Jan 8, 2010·BJU International·Roger S KirbyNoel Clarke
Jul 15, 2020·International Journal of Urology : Official Journal of the Japanese Urological Association·Hendrik Van Poppel, Per-Anders Abrahamsson
May 6, 2020·Journal of Clinical Medicine·Se Young ChoiChoung-Soo Kim
Mar 3, 2018·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Nur-Vaizura MohamadKok-Yong Chin
Apr 4, 2017·The Journal of Clinical Investigation·Anna C Groner, Myles Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.